

EDITED BY  
GREGORY D. CASCINO | JOSEPH I. SIRVEN  
WILLIAM O. TATUM

# EPILEPSY

SECOND EDITION



WILEY Blackwell



## **Epilepsy**



# Epilepsy

Second Edition

*Edited by*

*Gregory D. Cascino*  
*Mayo Clinic*  
*Rochester, MN, USA*

*Joseph I. Sirven*  
*Mayo Clinic*  
*Jacksonville, FL, USA*

*William O. Tatum*  
*Mayo Clinic*  
*Jacksonville, FL, USA*

**WILEY** Blackwell

This edition first published 2021  
© 2021 John Wiley & Sons, Ltd

*Edition History*

John Wiley & Sons (1e, 2011)

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at <http://www.wiley.com/go/permissions>.

The right of Gregory D. Cascino, Joseph I. Sirven and William O. Tatum to be identified as the author(s) of this the editorial material in this work has been asserted in accordance with law.

*Registered Office(s)*

John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA

John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

*Editorial Office*

9600 Garsington Road, Oxford, OX4 2DQ, UK

For details of our global editorial offices, customer services, and more information about Wiley products visit us at [www.wiley.com](http://www.wiley.com).

Wiley also publishes its books in a variety of electronic formats and by print-on-demand. Some content that appears in standard print versions of this book may not be available in other formats.

*Limit of Liability/Disclaimer of Warranty*

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting scientific method, diagnosis, or treatment by physicians for any particular patient. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

*Library of Congress Cataloging-in-Publication Data*

Names: Cascino, Gregory, editor. | Sirven, Joseph I., editor. | Tatum, William O., IV, editor.

Title: Epilepsy / edited by Dr Gregory D. Cascino, Dr Joseph I. Sirven, Dr William O. Tatum.

Other titles: Adult epilepsy

Description: Second edition. | Hoboken, NJ : Wiley-Blackwell, 2021. |

Preceded by Adult epilepsy / edited by Gregory D. Cascino and Joseph I Sirven. 2011. | Includes bibliographical references and index.

Identifiers: LCCN 2020027892 (print) | LCCN 2020027893 (ebook) | ISBN

9781119431824 (cloth) | ISBN 9781119431930 (Adobe PDF) | ISBN

9781119432005 (epub)

Subjects: MESH: Epilepsy

Classification: LCC RC372.3 (print) | LCC RC372.3 (ebook) | NLM WL 385 |

DDC 616.85/3-dc23

LC record available at <https://lcn.loc.gov/2020027892>

LC ebook record available at <https://lcn.loc.gov/2020027893>

Cover Design: Wiley

Cover Image: © Andrus Ciprian/Shutterstock

Set in 9.5/12.5pt STIXTwoText by SPi Global, Chennai, India

This book is dedicated to Dr. Frank W. Sharbrough who, approximately 50 years ago, developed a contemporary epilepsy surgery program at the Mayo Clinic. Frank was a pioneer in EEG monitoring techniques and involved in innovations in electrocorticography, neuroimaging and surgical strategies. He was a Mayo Clinic “distinguished clinician” and adored by his patients and their families. His lasting legacy is the integration of multiple disciplines including neurosurgery, neuroradiology and basic research at our institution in the care and management of people with epilepsy. Frank embodied the basic concept inherent in a successful epilepsy center: “the power of talent and teamwork.”





## Contents

<b>Preface</b>	xxiii
<b>Foreword</b>	xxv
<b>List of Contributors</b>	xxvii

### **Section I Epilepsy: Epidemiology, Diagnostic Evaluation and Co-Morbidities 1**

<b>1</b>	<b>Introduction and Epidemiology 3</b>
	<i>Joseph I. Sirven and Gregory D. Cascino</i>
	Incidence and Prevalence of Epilepsy 3
	Incidence and Prevalence of Acute Symptomatic Seizures 5
	Looking Beyond Epidemiology: The State of Epilepsy Care in the United States 6
	Risk Factors for Epilepsy 7
	Conclusion 8
	References 8
<b>2</b>	<b>Classification of Seizures and the Epilepsies 11</b>
	<i>Elaine C. Wirrell</i>
	Introduction 11
	Why Is Classification Important? 11
	Clinical 12
	Epidemiology 12
	Classification Scheme 12
	Level 1: Seizure Types 13
	Focal Onset Seizures 13
	Generalized Onset Seizures 14
	Unknown Onset Seizures 14
	Level 2: Epilepsy Based on Seizure Type 15
	Focal Epilepsy 15
	Generalized Epilepsy 15
	Generalized and Focal Epilepsy 15

	Unknown if Generalized or Focal Epilepsy	15
	Level 3: Epilepsy Syndrome	15
	Determination of Etiology	17
	Specific Etiologies	18
	Genetic	18
	Structural	18
	Metabolic	18
	Immune	18
	Infectious	19
	Unknown	19
	Comorbidities	19
	Epileptic Encephalopathy	19
	Developmental Encephalopathy	19
	Natural History of Epilepsies	20
	References	20
<b>3</b>	<b>Etiology and Pathology of Epilepsy</b>	<b>23</b>
	<i>Katherine C. Nickels and Katherine Noe</i>	
	Introduction	23
	Provoked Seizures	24
	Etiologic Classification of Epilepsy	25
	Genetic	25
	Structural	28
	Infectious	30
	Metabolic	30
	Autoimmune	31
	Summary	32
	References	32
<b>4</b>	<b>Genetics of Epilepsy</b>	<b>37</b>
	<i>Anthony L. Fine, Lily C. Wong-Kisiel and Raj D. Sheth</i>	
	Introduction	37
	Genetic Testing	38
	Genotype-Phenotype correlation	39
	Precision Medicine in Epilepsy Genetics	40
	Selected Genetic Epilepsy Syndromes	41
	Neurocutaneous Disorders	41
	Tuberous Sclerosis Complex (TSC)	41
	Sturge-Weber Syndrome (SWS)	43
	Malformations of Cortical Developments (MCD)	44
	Neurodevelopmental Disorders	46
	Progressive Myoclonic Epilepsies (PME)	46
	Familial Focal Epilepsies	51
	Autosomal Dominant Sleep-Related Hypermotor Epilepsy (ADSHE)	51

Autosomal Dominant Focal Epilepsy with Auditory Features	51
GRIN2A and CSWS/Landau–Kleffner Syndrome	54
Conclusion	54
References	54

## 5 Burden of Epilepsy 63

*J. Layne Moore, Amy Z. Crepeau and Gregory D. Cascino*

Introduction	63
Psychosocial Considerations	63
Psychological Distress	64
Stigma	64
Cognitive Effects	65
Behavioral Risk Factors	65
Smoking	65
Health and Disability	66
Morbidity	66
Economic Costs	67
Employment	68
Driving	69
Impact of Treatment with Antiseizure Drugs	70
Conclusion	70
References	70

## 6 EEG and Epilepsy 77

*Anteneh M. Feyissa, Gregory A. Worrell and Terrence D. Lagerlund*

Introduction	77
Types and Techniques of Recording	78
Routine Scalp EEG	78
Prolonged Video EEG Monitoring	80
Methods of Recording	80
Activation Procedures	81
Artifacts	82
Interictal EEG	82
Focal Interictal Epileptiform Discharges	84
Generalized Interictal Epileptiform Discharges	85
Clinical Utility of Interictal Epileptogenic Discharges	86
Ictal EEG Findings in Epilepsy	88
Focal Epilepsy	88
Generalized Epilepsy	89
EEG Source Localization and Epilepsy	90
The Forward Problem	90
The Inverse Problem	91
MEG and Source Localization and Epilepsy	93
Conclusion	94
References	95

- 7 Neuroimaging in Epilepsy 99**  
*Benjamin H. Brinkmann, Elson L. So, Robert E. Watson and Amy L. Kotsenas*  
Introduction 99  
Computerized Tomography (CT) 99  
Magnetic Resonance Imaging (MRI) 100  
    MRI Safety Consideration with Implanted Devices 102  
    7 T MRI 102  
Positron Emission Tomography (PET) 102  
Single Photon Emission Computed Tomography (SPECT) 105  
Functional Magnetic Resonance Imaging (fMRI) 107  
Image Processing 108  
Conclusion 110  
References 111
- 8 The Evaluation of Nonepileptic Paroxysmal Events 117**  
*Sara Dawit and Joseph F. Dratzkowski*  
Introduction 117  
Syncope 119  
Transient Ischemic Events 121  
Transient Global Amnesia (TGA) 122  
Movement Disorders 122  
Sleep Disorders 123  
Psychogenic Nonepileptic Seizures (PNES) 124  
Autoimmune Neurologic Disorders Associated with Epilepsy 125  
Conclusion 126  
References 127
- 9 Sleep, Sleep Disorders, and Epilepsy 133**  
*Diego Z. Carvalho, J. Layne Moore and Erik K. St. Louis*  
Background/Introduction 133  
Epidemiology of Sleep-Related Seizures and Epilepsies 134  
Sleep and Circadian Physiology for the Epileptologist 134  
Pathophysiology and Mechanisms of Sleep-Related Interictal Epileptiform Discharges and Seizures, and Epileptic Perturbation of the Sleep State 136  
Common Sleep-Related Epilepsies 137  
Diagnostic Approach and Treatment of Sleep-Related Epilepsies 139  
Differential Diagnosis of Other Common Nocturnal Events and Mimickers of Sleep-Related Epilepsies 140  
Diagnosis and Treatment of Sleep Comorbidities in Epilepsy: Obstructive Sleep Apnea, Insomnia, and Restless Legs Syndrome 140  
Sleep and Risk of Sudden Unexpected Death in Epilepsy (SUDEP) 142  
Conclusions 142  
References 143

**Epilepsy Journey: Identification of a Genetic Etiology for Epilepsy 147***Anthony L. Fine, Lily C. Wong-Kisiel and Raj D. Sheth*

Patient Case 147

References 151

**Epilepsy Journey 2: Evaluation of Spells in Adults 153***David B. Burkholder*

Case 1 153

Case 2 155

Case 3 155

Case 4 155

Case 5 156

**Epilepsy Journey 3: The Pediatric Patient with Spells: Recommendations for Evaluation 157***Katherine C. Nickels and Elaine C. Wirrell*

Is the Event Due to a Seizure and Is It Likely to Recur? 157

If the Event Was Not Felt to be Seizure-Related, What Type of Non-epileptic Event Was It? 159

If the Event Was Felt to be Seizure-Related, What Type of Seizure Was it and Is the Event Part of an Epilepsy Electro-Clinical Syndrome? 161

References 161

**Epilepsy Journey 4: Transitioning from Pediatric to Adult Epilepsy Clinic 165***Gregory D. Cascino, Katherine C. Nickels and Elaine C. Wirrell*

What Is Transition? 165

References 168

**Section II Epilepsy: Treatment of Epilepsy: Non-Surgical Therapy 169****10 First Seizure 171***Scott Spritzer and Omar Danoun*

Background and Epidemiology of First-Time Seizures 171

Causes of Acute Symptomatic Seizures 172

Evaluation of a First Seizure 173

Treatment after a First Seizure 174

Summary 175

References 175

**11 Antiseizure Medication Therapy 179***Kiran M. Kanth, Sarah Clark and Jeffrey W. Britton*

Introduction 179

ASM Selection 179

Seizure Type	179
Pharmacokinetics and ASM Selection	180
Mechanism of Action	183
Comorbidities	183
Side-Effect Profile	183
Drug–Drug Interactions	183
Titration Regimens	183
Cost of ASM	183
The ASMs: Summary of Clinical Use, Pharmacokinetics, and Efficacy	189
Brivaracetam	194
Indications, Usage, and Potential Side Effects	194
Dosage, Pharmacokinetics, and Potential Interactions	194
Carbamazepine	194
Indications, Usage, and Potential Side Effects	194
Dosage, Pharmacokinetics, and Potential Interactions	194
Clonazepam	195
Indications, Usage, and Potential Side Effects	195
Dosage, Pharmacokinetics, and Potential Interactions	195
Divalproex Sodium (Valproic Acid, Valproate)	195
Indications, Usage, and Potential Side Effects	195
Dosage, Pharmacokinetics, and Potential Interactions	196
Eslicarbazepine Acetate	196
Indications, Usage, and Potential Side Effects	196
Dosage, Pharmacokinetics, and Potential Interactions	196
Ethosuximide	196
Indications, Usage, and Potential Side Effects	196
Dosage, Pharmacokinetics, and Potential Interactions	197
Gabapentin	197
Indications, Usage, and Potential Side Effects	197
Dosage, Pharmacokinetics, and Potential Interactions	197
Efficacy	197
Lacosamide	198
Indications, Usage, and Potential Side Effects	198
Dosage, Pharmacokinetics, and Potential Interactions	198
Efficacy	198
Lamotrigine	198
Indications, Usage, and Potential Side Effects	198
Dosage, Pharmacokinetics, and Potential Interactions	199
Efficacy	199
Levetiracetam	199
Indications, Usage, and Potential Side Effects	199
Dosage, Pharmacokinetics, and Potential Interactions	200
Efficacy	200
Oxcarbazepine	200
Indications, Usage, and Potential Side Effects	200

	Dosage, Pharmacokinetics, and Potential Interactions	200
	Efficacy	201
	Perampanel	201
	Indications, Usage, and Potential Side Effects	201
	Dosage, Pharmacokinetics, and Potential Interactions	201
	Phenytoin	201
	Indications, Usage, and Potential Side Effects	201
	Dosage, Pharmacokinetics, and Potential Interactions	202
	Phenobarbital	202
	Indications, Usage, and Potential Side Effects	202
	Dosage, Pharmacokinetics, and Potential Interactions	202
	Primidone	203
	Indications, Usage, and Potential Side Effects	203
	Dosage, Pharmacokinetics, and Potential Interactions	203
	Pregabalin	203
	Indications, Usage, and Potential Side Effects	203
	Dosage, Pharmacokinetics, and Potential Interactions	203
	Efficacy	204
	Tiagabine	204
	Indications, Usage, and Potential Side Effects	204
	Dosage, Pharmacokinetics, and Potential Interactions	204
	Efficacy	204
	Topiramate	204
	Indications, Usage, and Potential Side Effects	204
	Dosage, Pharmacokinetics, and Potential Interactions	205
	Efficacy	205
	Zonisamide	205
	Indications, Usage, and Potential Side Effects	205
	Dosage, Pcal Interactions	205
	Efficacy	206
	Subspecialty ASMs	206
	Cannabidiol	206
	Indications, Usage, and Potential Side Effects	206
	Clobazam	207
	Felbamate	207
	Rufinamide	208
	Stiripentol	208
	Vigabatrin	209
	References	210
<b>12</b>	<b>Epilepsy in Women</b>	<b>217</b>
	<i>Katherine Noe</i>	
	Introduction	217
	Hormonal Influences on Epilepsy	217
	Reproductive Health in Women with Epilepsy	219

- Reproductive Dysfunction 219
- Pregnancy in Women with Epilepsy 220
  - Birth Defects 220
  - Seizure Control 222
  - Safety 222
- Breast Feeding 223
- Contraception for Women on Antiepileptic Medication 223
- Menopause in Women with Epilepsy 224
- References 224

**13 Treating Children with Epilepsy: Antiepileptic Medications (AEDs) 229**

- Raj D. Sheth*
- Introduction 229
- Initial Unprovoked Seizure 230
- AED Selection 230
  - Monotherapy over Polytherapy where Possible 230
  - Consideration of Formulation and Pharmacokinetics 230
  - Puberty and AED Selectin 231
  - Oral Contraceptives and Pregnancies 231
  - Adverse Effects 232
  - Screening Labs 232
- AEDs in Pediatric Epilepsy 232
  - Valproate 232
  - Ethosuximide 233
  - Levetiracetam 233
  - Clobazam 234
  - Lamotrigine 234
  - Perampanel 235
  - Vigabatrin 235
  - Adrenocorticotropin (ACTH) 236
  - Adherence to AED Therapy 236
  - AEDs for Sport Participation and Driving 237
- References 237

**14 Dietary Therapy in Epilepsy 239**

- Katherine C. Nickels and Elaine C. Wirrell*
- Introduction 239
- Mechanism of Action 239
  - Formulations of the Ketogenic Diet 240
- Classical 240
- Medium-Chain Triglyceride (MCT) Diet 240
- Modified Atkins Diet (MAD) 240
- Low Glycemic Index Treatment (LGIT) Diet 240
- Indications for Dietary Therapy 241
- Starting the Diet 242



	Pre-Diet Counseling and Testing	242
	Initiating the Diet	242
	Supplements	243
	Management of Concurrent Medications	243
	Safety and Monitoring for Adverse Effects	244
	Efficacy Data	245
	Weaning the Ketogenic Diet	245
	Conclusions	246
	References	246
<b>15</b>	<b>Autoimmune Epilepsy Disorders</b>	<b>249</b>
	<i>Jeffrey W. Britton, Eoin P. Flanagan, Andrew McKeon and Sean J. Pittock</i>	
	Epidemiology	249
	Etiologies and Mechanisms	250
	Clinical Presentation	253
	Scoring Systems in the Evaluation and Treatment of Autoimmune Epilepsy	254
	Diagnostic Testing in Autoimmune Epilepsy	254
	EEG	254
	Serological Findings (Serum and CSF)	256
	Neuroimaging	259
	Brain MRI	259
	18-Fluorodeoxyglucosae (FDG) – Positron Emission Tomography (PET)	259
	Imaging in Cancer Detection in Autoimmune Epilepsy	260
	Treatment	261
	Acute Treatment and General Approach	261
	Treatment of Specific Neural Antibody-Associated Encephalitides	266
	NMDA-R Antibody Encephalitis	266
	LG11 Antibody Encephalitis	266
	Other Neural Antibodies	266
	Maintenance Immunosuppression	266
	Future Therapies	267
	Cancer Treatment	267
	Antiseizure Medication Therapy and Other Treatments	267
	Conclusion	268
	References	269
<b>16</b>	<b>Discontinuation of Antiseizure Medication</b>	<b>275</b>
	<i>Jamal F. Khattak and Jeffrey W. Britton</i>	
	Introduction	275
	Methodological Issues in Studies Evaluating ASM Discontinuance	276
	Seizure Recurrence Rates After ASM Discontinuance	276
	Factors that Predict Seizure Recurrence After ASM Discontinuance	277
	Age, Duration, and Timing	277
	Epilepsy Syndromes and Etiology	278
	Seizure Characteristics	279

- Other Demographic and Clinical Factors 279
- Antiseizure Medication Use 279
- Role of Electroencephalogram (EEG) 279
- Risk-Prediction Models 280
- Practical Considerations of ASM Discontinuance 282
- References 283
  
- 17 Investigational Therapy and Drug Approval Process within the US and Cannabidiol 287**  
*Gregory Sprout, Joseph I. Sirven and Gregory D. Cascino*
- Introduction 287
- US Food and Drug Administration 288
- Pharmaceutical Development and Approval Process 289
  - Five Stages 289
- Discovery and Development 289
- Pre-Clinical Research 290
- Clinical Research 290
- FDA Review 292
- FDA Action and Post-Approval Risk Assessment 293
- Expedited Approval Tracks for Pharmaceutical Therapies 293
  - Fast Track 293
  - Breakthrough Therapy 293
  - Accelerated Approval 295
  - Priority Review 295
- Generic Drugs 295
- Medical Device Development and Approval Process 296
- Cannabidiol for Epilepsy 297
- Government's Role in Regulation 298
- Current Pipeline, Futuristic Therapies, and the Regulatory Implications 298
- References 299
  
- 18 Devices to Monitor and Track Your Epilepsy 301**  
*Nicholas M. Gregg and Amy Z. Crepeau*
- Introduction 301
- Generators and Origins of Biosignals 302
  - EEG Based Sensors (Scalp, Sub-Scalp, Intracranial) 302
- Scalp EEG 302
- Subcutaneous EEG 302
- Intracranial EEG 303
  - Extracerebral Sensors 303
- Accelerometry/Gyroscopes/Magnetometers 303
- Electrodermal Activity (EDA) 303
- Surface Electromyography (EMG) 304

Cardiac and Respiratory Monitors	304
Photoplethysmography (PPG)	304
Electrocardiography (ECG)	304
Respiratory Effort Belt	304
Temperature Sensors	304
Mattress Sensors	305
Video and Radar-Based Devices	305
Seizure Dogs	305
Patient Self-Reported Seizure Diaries	305
Multimodal Detection Devices	305
Sensitivity, Specificity, False-Alarm Rates, and Receiver Operating Characteristic Curves	306
Seizure Detection for Different Types of Seizures	306
Commercially Available Devices	307
Cost	308
Conclusions	308
References	309

**Epilepsy Journey 5: Seizure Emergencies (Include status Epilepticus, Fires, Norse, Seizure First Aid, and Seizure Clusters)** 313

*Anteneh M. Feyissa, Matthew T. Hoerth and Eric T. Payne*

**Epilepsy Journey 6: The First seizure – How to Evaluate: Pediatric** 315

*Korwyn Williams*

References 316

**Epilepsy Journey 7: The First Seizure – How to Evaluate: Adult** 317

*Paul M. Magtibay and Joseph I. Sirven*

References 318

**Epilepsy Journey 8: Treating Epilepsy Second Seizure and beyond: How to Choose a Drug – An Algorithm** 321

*Amy Z. Crepeau*

References 322

**Epilepsy Journey 9: Treating Status Epilepticus: An Algorithm** 325

*Sara E. Hocker and Eric T. Payne*

**Epilepsy Journey 10: Withdrawal of ASDs in Adults: An Algorithm** 331

*Sarah A. Merrill, Kent R. Richter and Joseph I. Sirven*

Withdrawal of Anti-Seizure Drugs (ASDs) in Adults: A Treatment Algorithm 331

Timing of Anti-Seizure Drug Withdrawal 331

Timing and Rate of ASD Withdrawal 333

References 333

**Epilepsy Journey 11: Withdrawal of ASDs in Seizure-Free Patients Children: The Pediatric Neurologist's Perspective 335**

*Elaine C. Wirrell*

References 337

**Epilepsy Journey 12: Withdrawing ASDs in Adults after Epilepsy Surgery 339**

*Christian Rosenow, Luca Farrugia, Andrew Pines and Joseph I. Sirven*

References 341

**Epilepsy Journey 13: The Pregnant Patient with Epilepsy: An Algorithm 343**

*Katherine Noe*

**Section III Epilepsy: Treatment of Epilepsy: Surgical Management 345**

**19 Pre-surgical Evaluation 347**

*David B. Burkholder, Anthony L. Ritaccio and Cheolsu Shin*

Introduction 347

Patient Selection 347

    Epilepsy Type 347

    Drug Resistance 348

    Misconceptions About Epilepsy Surgery 349

    Patient Goals 349

Misconceptions About Who Is Appropriate for Surgery 350

Misunderstandings About Surgery and Outcomes 351

Diagnostic Evaluation 351

    Primary Evaluation 351

Magnetic Resonance Imaging (MRI) 352

Epilepsy Monitoring and Seizure Classification 352

Neuropsychology Testing 353

    Additional Evaluation 353

Single-Photon Emission Computed Tomography (SPECT) 354

Positron Emission Tomography 354

Magnetoencephalography 355

Electrical Source Imaging (ESI) 356

Intracarotid Amobarbital Procedure 356

Functional MRI 357

Surgically Remediable Epilepsy Syndromes 357

    Mesial Temporal Lobe Epilepsy 357

    Focal Cortical Dysplasia 358

    Tuberous Sclerosis 360

    Long-Term Epilepsy-Associated Tumors 361

    Vascular Lesions 361

- Pediatric Hemispheric Epilepsy Syndromes 361
  - Conclusion 361
  - References 362
  
- 20 Minimally Invasive Epilepsy Surgery 367**  
*Sanjeet S. Grewal, Robert E. Wharen Jr. and William O. Tatum*  
 Radiofrequency Thermoablation 367  
 Stereotactic Radiosurgery (SRS) 369  
 Laser Interstitial Thermal Therapy 371  
 Mesial Temporal Lobe 372  
 Specific Lesions 373  
 Minimally Invasive Corpus Callosotomy 374  
 Conclusion 374  
 References 374
  
- 21 Intracranial EEG Monitoring 381**  
*Jamie J. Van Gompel, Katherine Noe and Richard S. Zimmerman*  
 Introduction 381  
 Identifying Candidates for Invasive EEG Monitoring 381  
 Indications for Invasive EEG Monitoring 382  
 Choosing an Implantation Strategy: Benefits and Risks 383
  - Invasive EEG Using sEEG Electrodes: Technical Considerations 385
  - Invasive EEG Using Subdural Electrodes 388
 Conclusion 398  
 References 398
  
- 22 Surgical Strategies (Include Cortical Resection, Lesionectomy, Cortical Stimulation and Functional Mapping, Hemispherotomy) 401**  
*Angela Bohnen, W. Richard Marsh, Alfredo Quinones-Hinojosa and Kaisorn L. Chaichana*  
 Introduction 401
  - Surgical Procedures 402
 Lesionectomy 402
  - Temporal Lobe Epilepsy 403
 Anterior Temporal Lobectomy (ATL) 403  
 Selective Amygdalohippocampectomy 404
  - Cortical Stimulation and Functional Mapping 405
  - Hemispherotomy 406
  - Complications 406
  - Outcomes 407
 Seizure Control 407  
 Quality of Life 407  
 Cognition 408

Driving 408  
Timing of Surgery 408  
References 408

## 23 **Corpus Callosotomy** 413

*Elaine C. Wirrell, Lily C. Wong-Kisiel and Kai J. Miller*

Indications 413  
Surgical Techniques 414  
Evaluation of Callosotomy Extent 416  
Complications of Callosotomy 416  
Efficacy of Callosotomy 417  
    Multiple Subpial Transection 418  
Efficacy of MST in Landau Kleffer Syndrome 418  
Efficacy of MST in Other Cases Involving Eloquent Cortex 418  
Efficacy of Multiple Hippocampal Transection in Temporal  
Lobe Epilepsy 419  
    Hemispherectomy 419  
Pre-surgical Evaluations 419  
Surgical Techniques 420  
Complications 422  
Seizure Outcome / Efficacy 424  
Global Functional Outcome 425  
Surgical Failures/Re-Operations 426  
Conclusion 426  
References 426

## 24 **Neuromodulation for Epilepsy** 431

*Brian N. Lundstrom, Robert E. Wharen, Jr and William O. Tatum*

Introduction 431  
    Historical Context 431  
    Stimulation Approaches of VNS, RNS, and DBS 432  
    Efficacy and Safety of VNS, RNS, and DBS 433  
    Application of Stimulation Approaches and Other Considerations 435  
References 437

## 25 **Emerging Treatments for Epilepsy** 441

*Gregory A. Worrell, Benjamin H. Brinkmann, Brian N. Lundstrom and Matt Stead*

Introduction 441  
    Next-Generation Epilepsy Biomarker Discovery and Management  
    System 443  
    Pre-Clinical Testing of Next-Gen Epilepsy Management System in Canine  
    Epilepsy 444  
    Ethical Considerations 445  
Conclusions 446  
Acknowledgement 446  
References 446

<b>26</b>	<b>Seizure Forecasting in Epilepsy: From Computation to Clinical Practice</b>	<b>451</b>
	<i>Benjamin H. Brinkmann, Nicholas M. Gregg and Gregory A. Worrell</i>	
	Introduction	451
	Computational and Data Resources	452
	Devices and Ambulatory Monitoring	453
	New Devices and Ongoing Efforts	454
	Summary	456
	References	457
	<b>Epilepsy Journey 14: The Drug-Resistant Patient: Pre-surgical Evaluation and Surgery-Approach to the “Skip” Candidate</b>	<b>463</b>
	<i>Anteneh M. Feyissa and David B. Burkholder</i>	
	Discussion	465
	References	468
	<b>Epilepsy Journey 15: The Drug-Resistant Patient and Discordant Pre-surgical Evaluation</b>	<b>469</b>
	<i>Lily C. Wong-Kisiel, Elson L. So and Richard S. Zimmerman</i>	
	Case 1	469
	Case 2	471
	Discussion	472
	References	475
	<b>Epilepsy Journey 16: The Drug-Resistant Patient who is not a Candidate for Resective Surgery: An Approach to Neuromodulation</b>	<b>477</b>
	<i>Anthony L. Ritaccio and William O. Tatum</i>	
	Introduction	477
	Case Discussion	477
	Conclusion	480
	References	482
	<b>Epilepsy Journey 17: Epilepsy Surgery in Pediatric Patients</b>	<b>483</b>
	<i>Raj D. Sheth, Kai J. Miller and Elaine C. Wirrell</i>	
	Pre-surgical Evaluation: Antiseizure Drugs (ASDs)	484
	Seizure Semiology	485
	Identification of Drug-resistant Epilepsy	485
	EEG and Epilepsy Monitoring Unit (EMU) planning	486
	Epilepsy Pre-Surgical Conference	487
	Intracranial EEG Monitoring	487
	Surgical Treatment of Neocortical Focal Epilepsy	488
	Hemispheric Epilepsy	488
	Drug-resistant Generalized Epilepsy and Non-localized Focal Epilepsy	489
	References	489
	<b>Index</b>	<b>491</b>





## Preface

This book represents the efforts of the Mayo Clinic Epilepsy Enterprise encompassing colleagues at the three comprehensive Level IV epilepsy programs in Jacksonville, FL., Phoenix, AZ., and Rochester, MN. The authors of this monograph are actively involved in patient care, clinical research and education at the Mayo Clinic and our associated institutions including the Mayo Clinic Health System. Individuals from multiple disciplines including pediatric and adult epilepsy, EEG, autoimmune neurology, sleep medicine, neurosurgery, neuroradiology, and basic research dedicated to the care and management of people with epilepsy contributed material to the chapters. Every attempt has been made to provide a contemporary and current presentation addressing challenging diagnostic and therapeutic issues that confront the healthcare provider evaluating patients with suspected seizure disorders. Moreover, our epilepsy journey sections that accompany many of our chapters, provide a glimpse into the decision-making process that our authors utilize in managing complex epilepsy patients. The goal of any such book is to become a *trusted, dependable and used* guide providing a reliable source of *useful* information that improves the quality of life of people with epilepsy. Our hope is that we have accomplished that goal!

Greg Cascino  
*Rochester, MN*

Joe Sirven  
*Jacksonville, FL*

Bill Tatum  
*Jacksonville, FL*  
*July 2019*



## Foreword

I'm delighted to hear that this book will be dedicated to Dr. Frank Wilson Sharbrough III on his 50th anniversary of joining the Mayo Clinic. Frank certainly deserves this honor. Frank is both an outstanding neurologist as well as an accomplished electroencephalographer. Once he joined the Mayo Clinic in the late 1960s, he rapidly absorbed the philosophy of the "Mayo Clinic school of electroencephalography" and was one of the most distinguished and beloved EEG teachers. However, in addition, he maintained and grew his clinical skills, particularly in epilepsy. These qualifications put him in an ideal position to pioneer an epilepsy surgery program at the Mayo clinic that now has grown to become one of the leading epilepsy surgery programs in the USA.

I was fortunate to have Frank as my EEG teacher during the four years I spent in Rochester studying clinical neurophysiology. Frank always had time to answer my questions and to review an "interesting" EEG. Besides, integrating the EEG findings with the actual clinical situation, made his teachings particularly valuable. There is no doubt that Frank's teachings greatly influenced the development of EEG and Epilepsy in the USA as well as worldwide. We certainly feel privileged and most thankful for his mentorship.

*Hans Lüders, MD, PhD*  
Professor of Neurology  
Cleveland Medical Center  
OH, USA



## List of Contributors

**Angela Bohnen**

Department of Neurology  
Division of Epilepsy  
Mayo Clinic  
Phoenix, AZ  
USA

**Benjamin H. Brinkmann**

Departments of Neurology, Physiology and  
Biomedical Engineering  
Division of Epilepsy  
Mayo Clinic  
Rochester, MN  
USA

**Jeffrey W. Britton**

Department of Neurology  
Division of Epilepsy  
Mayo Clinic  
Rochester, MN  
USA

**David B. Burkholder**

Department of Neurology  
Division of Epilepsy  
Mayo Clinic  
Rochester, MN  
USA

**Diego Z. Carvalho**

Department of Neurology  
Mayo Clinic  
Rochester, MN  
USA

**Gregory D. Cascino**

Department of Neurology  
Division of Epilepsy  
Mayo Clinic  
Rochester, MN  
USA

**Kaisorn L. Chaichana**

Department of Neurosurgery  
Mayo Clinic  
Jacksonville, FL  
USA

**Sarah Clark**

Department of Pharmacy  
Mayo Clinic  
Rochester, MN  
USA

**Amy Z. Crepeau**

Department of Neurology  
Division of Epilepsy  
Mayo Clinic  
Phoenix, AZ  
USA

**Omar Danoun**

Department of Neurology  
Henry Ford Hospital  
Detroit, MI  
USA

**Sara Dawit**

Department of Neurology  
Division of Epilepsy  
Mayo Clinic  
Phoenix, AZ  
USA

**Joseph F. Drazkowski**

Department of Neurology  
Division of Epilepsy  
Mayo Clinic  
Phoenix, AZ  
USA

**Luca Farrugia**

Department of Neurology  
Mayo Clinic  
Phoenix, AZ  
USA

**Anteneh M. Feyissa**

Department of Neurology  
Division of Epilepsy  
Mayo Clinic  
Jacksonville, FL  
USA

**Anthony L. Fine**

Department of Neurology  
Divisions of Child and Adolescent  
Neurology and Epilepsy  
Mayo Clinic  
Rochester, MN  
USA

**Eoin P. Flanagan**

Department of Neurology  
Division of Multiple Sclerosis and  
Autoimmune  
Mayo Clinic  
Rochester, MN  
USA

**Sanjeet S. Grewal**

Department of Neurosurgery  
Mayo Clinic  
Jacksonville, FL  
USA

**Nicholas M. Gregg**

Department of Neurology  
Division of Epilepsy  
Mayo Clinic  
Rochester, MN  
USA

**Sara E. Hocker**

Department of Neurology  
Mayo Clinic  
Rochester, MN  
USA

**Matthew T. Hoerth**

Department of Neurology  
Division of Epilepsy  
Mayo Clinic  
Phoenix, AZ  
USA

**Kiran M. Kanth**

Department of Neurology  
Division of Epilepsy  
Mayo Clinic  
Rochester, MN  
USA

**Jamal F. Khattak**

Department of Neurology  
Division of Epilepsy  
Mayo Clinic  
Rochester, MN  
USA

**Amy L. Kotsenas**

Department of Neuroradiology  
Mayo Clinic  
Rochester, MN  
USA